A Case of SGLT2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis.
Citation: Cureus. 14(10):e30106, 2022 Oct.PMID: 36381906Institution: MedStar Union Memorial HospitalDepartment: Internal Medicine | Internal Medicine ResidencyForm of publication: Journal ArticleMedline article type(s): Case ReportsSubject headings: IN PROCESS -- NOT YET INDEXEDYear: 2022ISSN:- 2168-8184
Item type | Current library | Collection | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Journal Article | MedStar Authors Catalog | Article | 36381906 | Available | 36381906 |
While rare, serious adverse effects including euglycemic diabetic ketoacidosis (EDKA) have been associated with sodium-glucose cotransporter-2 inhibitor (SGLT2i) use. We present an interesting case of SGLT2i-induced EDKA occurring two years after initiation of therapy. Most patients with EDKA recover with prompt recognition and treatment. Patient education about identifying early signs remains a cornerstone of early identification and response to SGLT2i-induced EDKA. Copyright © 2022, Rao et al.
English